Rasburicase Dosage
This dosage information may not include all the information needed to use Rasburicase safely and effectively. See additional information for Rasburicase.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Geriatric Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Hyperuricemia Secondary to Chemotherapy
Recommended dose: 0.2 mg/kg as a 30 minute intravenous infusion daily for up to 5 days
Dosing beyond 5 days or administration of more than one course is not recommended.
Usual Geriatric Dose for Hyperuricemia Secondary to Chemotherapy
Recommended dose: 0.2 mg/kg as a 30 minute intravenous infusion daily for up to 5 days
Dosing beyond 5 days or administration of more than one course is not recommended.
Usual Pediatric Dose for Hyperuricemia Secondary to Chemotherapy
Recommended dose: 0.2 mg/kg as a 30 minute intravenous infusion daily for up to 5 days
Dosing beyond 5 days or administration of more than one course is not recommended.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Severe hypersensitivity reactions including anaphylaxis have occurred at any time during treatment with rasburicase, including the first dose. Signs and symptoms of these reactions include dyspnea, hypoxia, hypotension, bronchospasm, chest pain and tightness, shock, and/or urticaria. The drug should be immediately and permanently discontinued in any patient developing clinical evidence of a serious hypersensitivity reaction.
In patients identified as having developed methemoglobinemia, the drug should be discontinued immediately and permanently.
Rasburicase can cause enzymatic degradation of the uric acid in blood/plasma/serum samples left at room temperature resulting in false low plasma uric acid assay readings. To ensure accurate measurement, blood must be collected into pre-chilled tubes containing heparin anticoagulant and immediately immersed and maintained in an ice water bath. Plasma samples must be assayed within four hours of sample collection.
Rasburicase is contraindicated in patients deficient in glucose-6-phosphate dehydrogenase and in any patient diagnosed with or developing hemolysis. Patients at higher risk of glucose-6-phosphate dehydrogenase (G6PD) deficiency should be screened before the start of therapy because rasburicase can cause severe hemolysis.
Patients at risk of tumor lysis syndrome on rasburicase should receive intravenous hydration according to standard medical practice for the management of plasma uric acid.
Dialysis
There are no data on the dialysis clearance of rasburicase.
Other Comments
Dosage is mixed in normal saline to a total volume of 50 mL and given over 30 minutes. Do not use filters for the infusion.
Chemotherapy should be started 4 to 24 hours after the initial dose of rasburicase.
